HIGHLIGHTS
- who: Ying Chen from the Carcinoma in China Department of Drug Clinical Trial Administration Office, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital have published the research work: Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China, in the Journal: Nutritional nerve therapy of November/12,/2018
- what: Based on the ATTRACTION-3 trial data, the study attempted to assess the cost-effectiveness of nivolumab immunotherapy and paclitaxel/docetaxel chemotherapy treatment alternatives by measuring and comparing therapy costs and effectiveness from the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.